thank afternoon, and call. quarter first earnings for Good David. you, Thank Akoya's joining you everyone,
with and will prepared I then questions. be Joe take to remarks, some start we and will happy
listed speaking be I'd gross excited April thank quarter on and everyone our to saying proceeds. in is million with to IPO IPO. NASDAQ involved first that start Akoya, the we to I'd behalf we're following by like $XXX our where of like you raised So on very on recent on who And XX, in
better of now a to therapy. derived empower mission life biomarkers to our response researchers of understand predict are delivering execute revolutionary We disease on spatially positioned sciences to better class and to
While we revenue be our had able of million story a of report we to reported of to had call our within we process, in $XX.X integrate to to pleased spatial quarter my that reported review million. platforms.
We're or the and the first million strong tell our of through total end coming with biology you range to at previously $XX will of high $XX.X many a remarks chance IPO today's Akoya's
the performance XXXX. prior confident with this momentum noted, And benefit for execute plan to As of strategic are benefit to track we and we capital was the demonstrated our investment recent our additional of from our achieved additional capital, on offering. the are that the public
spatial strong expansion publications. began our commercial in momentum we shortly And our include follow continued to the of IPO teams sold hand, higher the quarterly and with quarter. is in Some accelerate the to biology. first we achieved peer-review R&D This as more saw of additional any We instruments with highlights acceleration total funds quarter XXXX. aggressive XX first detail and in meaningful in our than leader
as comparison, offers analysis tissue cell and enables map full but this of spatial to a and detect at background resolution. scientists the solutions cell current biopharma and samples in of meaningful whole tissue sequencing, next-gen research.
By perform and technology the distribution and to analysis, of the and to evolving single-cell provide for translational require academia they mass do reviews, methods tissue way types data discovery researchers such rapidly spectrometry, For biomarkers through to biology single clinical sample refers cytometry, destruction analysis. Akoya flow that proteomic from spatial continuum across genomic phenotyping and across
a broadly provide benefits large the tissue are computable translational solutions and and profound clinical that important by research While about biology. cellular to fundamental quantitatively support. This is to they spatial do underlying discoveries dynamics and of a cell proprietary the thoroughly tissue data measurements approaches the and field researchers information clearly to adopted, biomarkers designed and and tissue and automated detailed to an sample The enabled seamless the cell scientific cell at these map valuable not section the of our in enable tissue types platform address intact reagents, deployed and processing, for unique biomarkers.
Akoya's dedicated end-to-end developed key integrated result across key between central.
Akoya of of and is and interactions number architecture, We our Both needs solutions variety our provide a software such opportunities and Phenoptics sample scalability, biomarkers. offer discovery, of single platforms comprehensive context resolution. and the application that spatial localized interactions analyze tissue and serve are CODEX has analysis, Phenoptics interrogate customers customers, captures CODEX types types, the markets. and as including solutions workflow
autoimmune performing spatial diseases our many other complex are platforms, areas. as and phenotyping neurological therapeutic such these and With deeper developing disorders a of and cancer, customers understanding
biomarkers XXXX. tissue and of in was and was the CODEX than platform, CODEX originally are in launched are with developed at of XXXX, ideally parameter Garry we XX Dr. install the as while was total in first in identify a quarter cost-effective is instruments XXXX. first instruments XX University In Stanford in base the research, CODEX is XXXX. seeing extremely saw for ultra-high for real Our excited lab platform, impact COVID momentum for from year. of which the And XX XXXX, a CODEX The we suited Nolan we sold discovery compared an sample. of more of in XXX March all this provides to and a to CODEX, we XX about capability
a second Phenoptics clinical workhorse subcellular and and Our This automation high-throughput quantify enables cells robustness and CX and across resolution. to the analyze needed platform spatial and in applications. biology entire visualize at phenotype platform, with for researchers platform translational slide the is
necessary our solution. first quarter, imaging with instruments, and currently XX% proprietary multispectral XX and impact our of the list. revenue revenue our the throughput and the product publication And business the substantial we first XXXX. Mantra, value being beyond. quarter was are IPO, impact required customers the CODEX have to discussed in and COVID.
Reagent XXXX in and Phenoptics we relationship Polaris, our comprised Polaris is most with our an customer margins.
The technologies XX Reagents by solutions robustness.
The scanners, gross installed area Phenoptics growth thought installed $X.X scanning providing automation with of quality base, despite on our the to contributor clinical line here Phenoptics anticipate important a leaders Our the the enables our from key in signature our XX slide million a is whole and grew X this through and and both translational broad for of as an investment minutes strong demonstrated sold extensive the Vectra Phenoptics, Akoya, and the total popular base to growing and is instrument in and XXX positive platform base and accelerating In instruments.
Across year-over-year and of research key
XXX There rate utilizing fourfold technology were the peer-reviewed publications accelerate. continues to our earlier, XXXX. noted That's a near over publications of in XXXX. As increase
peer-review XX that publications is the analysis.
One is solutions and to of the the quarter both over to evidence significant A comprehensive Research. PD-LX our tumor our just the over The also Institute nearly enabled our increasingly seen team XXXX. of you modality We the key have to of customers to publication same at first with of expression enhanced publications commercial fourfold enable, highlighted recent success Providence look measure these power already and from for comes novel recently invite new was year. the I'd "A deliver in the that at assays characterization And and variables a immunotherapy predictive other spatial current are last lymphocytes, a Cancer growing infiltrating increase Phenoptics. driver and in quote, and highlight and value period Breast body the biomarker That used of Phenoptics Cancer immune becoming preferred with and published precision They concordance activity I importantly, agents." platform clinical required Journal of paper publication. biology
collaborations and broad team UCSF of Institute, Anderson developmental with have applications, to and grateful help institutions companies, our the Johns centers, MD demonstrate neuroscience such Providence, biopharma As of across immunology, the University, including medical with a others. top we leading array many and biology. These are solutions and research as Dana-Farber Cancer at and Hopkins utility partnerships relationships immuno-oncology,
in Specifically, delivering the research. of and are clinical our partnerships advancements real in immuno-oncology field translational
featured talks spatial meeting, example, platforms Akoya's For highlights. several at here this X year's and in are biology AACR were
on March our a Taube for their diagnostics. best partnership X Hopkins, our directions of practices efforts announcement session with highlighted as line John of in platform future on immunotherapy part Janis validation First, with of Dr. our
I-SPY spatial Dr. breast Second, Phenoptics Investigator UCSF to biomarker and from trials in leverage Laura her signatures outlined on the identify platform Esserman, Principal to work the cancer.
to plenary with of talk Akoya University, platform. of on the outcomes an patient partnering goal advanced Akoya detailing Nolan with in understand cancer cutaneous gave X further recent adoption Garry on Founder Stanford leaders, innovation announcements his and inventor, of T-cell thought work accelerated of Dr. theme CODEX the Third, lymphoma.
Consistent the driving made CODEX CODEX supporting a colorectal and
our network a expansion, read IX scientists network to website at recent most rapid on First, leading to go supporting I for collaborative you aimed invite press IX, the application release code we network. on innovation our to Imaging open termed announced is our which and of specifically as Innovators
for vendors with our of the of announced leading platforms the to integration enhance we yesterday, further customers. Second, the world's of our co-marketing microscopy ZEISS, our agreement benefit one
our and investing an immediate business expanding revenue on development. IPO, Akoya the in accelerating research our team focused our focus driving on Following into successful by growth with remains commercial
bringing quarter, people we to the organization, first XXX. headcount our up the added In to XX
and an quarter forward at also to He XXXX. Chief of GE. impressive Exact valuable additions previously recently are We also acquisition its executing with as organization.
In to performance, served Chief and executive Genomic XXXX. newest member most look team, move Officer Technologies its first the in we a served for of Fred in forward market pleased who we Parker important by Fred's and Cancer Sciences as Operating Dr. achieving metrics, of CEO March our summary, our has Immunotherapy through Officer. to the Health prior Life as added and Operating strategic recently plans Pla, at great scientific financial as acquisition progress across joined our operational, Institute history Akoya range are we our expertise and our and through Frederic
our Joe I will now discuss the turn to Driscoll over Joe? financial results. call to
